Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smartphone app accurately measure depression?

NCT ID NCT06601140

Knowledge-focused Sponsor: Emobot Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether a smartphone app called EMOCARE can accurately track emotional changes in people with mild to severe depression. About 104 adults will use the app for 6 weeks while also filling out standard depression questionnaires. The goal is to see if the app gives results similar to those questionnaires and to learn about any problems users may face.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 104 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient of both sexes aged 18 or over. * Outpatient with unipolar depression (regardless of the time of the episode) (major depressive disorder). * Patient with an episode of major depression supported by PHQ-9 score greater than or equal to 5. * Patient with an episode of major depression supported by MADRS score greater than or equal to 7. * Patient accustomed to regular use of a smartphone and/or computer * Patient who, in the opinion of the investigator, will comply with the requirements of the protocol. * Patient affiliated to a social security scheme or beneficiary of such a scheme. * Patient who has received full information about how the clinical investigation shall be conducted and has signed an informed consent form. * Patient who reads and understands French. * Patient who has undergone clinical screening adapted to the clinical investigation. Exclusion Criteria: * Patient treated with antipsychotic drugs. * Patient with an unstable pathology that could interfere with the study. * Patient unable to communicate or cooperate with the investigator due to a low mental level, language difficulties or impaired cerebral function. * Patient with an active suicidal tendency or patient who has had a suicidal episode in the last 6 months * Patients with borderline personality disorders. * Patient with a contra-indication to the product(s) under evaluation. * Woman of childbearing age without effective contraception. * Pregnant woman, birthing or breastfeeding mother * Minor (not emancipated) * Incapacitated person

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Major depressive disorder (MDD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Major depressive disorder (MDD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier Universitaire de Nantes

    NOT_YET_RECRUITING

    Nantes, 44093, France

  • Centre Psychothérapique de Nancy

    NOT_YET_RECRUITING

    Laxou, 54521, France

  • Centre hospitalier Guillaume Régnier

    RECRUITING

    Rennes, 35000, France

  • Private psychiatric practice

    RECRUITING

    Agen, 47000, France

  • Private psychiatric practice

    TERMINATED

    Maxéville, 54320, France

  • Private psychiatric practice

    RECRUITING

    Nantes, 44000, France

  • Private psychiatric practice

    NOT_YET_RECRUITING

    Paris, 75013, France

  • Private psychiatric practice

    NOT_YET_RECRUITING

    Reims, 51000, France

  • Private psychiatric practice

    RECRUITING

    Saint-Grégoire, 35760, France

  • Private psychiatric practice

    RECRUITING

    Saint-Nazaire, 44600, France

  • Private psychiatric pratice

    RECRUITING

    Caen, 14000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.